CAC
NAUT icon

Cowen and Company’s Nautilus Biotechnolgy NAUT Stock Holding History

Cowen and Company’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-30,000
Closed -$303K – 666
2021
Q2 		$303K Buy
+30,000
New +$325K 0.02% 231

Other funds holding NAUT

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cowen and Company's NAUT Position: Q3 2021 in Review

Cowen and Company sold out of Nautilus Biotechnolgy (NAUT) in Q3 2021, closing a stake of 30,000 shares — an estimated $303K sold.

Cowen and Company first reported a position in NAUT in Q2 2021 and held it in 1 quarter. The position peaked at $303K in Q2 2021. 72 funds tracked by Wall St. Rank hold NAUT as of Q3 2021.

  • Cowen and Company reported no remaining Nautilus Biotechnolgy position as of Q3 2021 after selling out during the quarter.
  • Cowen and Company sold 30,000 Nautilus Biotechnolgy shares in Q3 2021, an estimated $303K.
  • Cowen and Company first reported a position in Nautilus Biotechnolgy in Q2 2021 and held it in 1 quarter.
  • Cowen and Company's Nautilus Biotechnolgy position peaked at $303K in Q2 2021.
  • 72 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.